Brokerages expect Ingevity (NYSE:NGVT) to announce $308.15 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Ingevity’s earnings, with the highest sales estimate coming in at $312.00 million and the lowest estimate coming in at $304.30 million. Ingevity posted sales of $260.30 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 18.4%. The firm is expected to announce its next earnings report on Wednesday, August 1st.
According to Zacks, analysts expect that Ingevity will report full year sales of $1.11 billion for the current financial year, with estimates ranging from $1.10 billion to $1.12 billion. For the next year, analysts expect that the company will post sales of $1.24 billion per share, with estimates ranging from $1.19 billion to $1.30 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Ingevity.
Ingevity (NYSE:NGVT) last announced its quarterly earnings data on Wednesday, May 2nd. The company reported $0.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.16. Ingevity had a net margin of 13.96% and a return on equity of 48.09%. The company had revenue of $235.20 million for the quarter, compared to the consensus estimate of $231.76 million. During the same period in the prior year, the firm posted $0.49 EPS. Ingevity’s revenue for the quarter was up 7.6% on a year-over-year basis.
NGVT stock traded up $2.79 during trading on Friday, hitting $82.89. 3,643 shares of the stock traded hands, compared to its average volume of 227,228. Ingevity has a 1 year low of $81.32 and a 1 year high of $81.40. The company has a market capitalization of $3.35 billion, a price-to-earnings ratio of 31.05, a price-to-earnings-growth ratio of 1.93 and a beta of 1.04. The company has a debt-to-equity ratio of 2.34, a quick ratio of 1.39 and a current ratio of 2.67.
Several hedge funds and other institutional investors have recently made changes to their positions in NGVT. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Ingevity by 50.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,420 shares of the company’s stock valued at $171,000 after acquiring an additional 807 shares during the last quarter. Quantbot Technologies LP boosted its holdings in shares of Ingevity by 1,735.5% during the 1st quarter. Quantbot Technologies LP now owns 2,588 shares of the company’s stock valued at $190,000 after acquiring an additional 2,447 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Ingevity during the 4th quarter valued at about $206,000. Greenwood Capital Associates LLC purchased a new stake in shares of Ingevity during the 4th quarter valued at about $223,000. Finally, Miles Capital Inc. purchased a new stake in shares of Ingevity during the 4th quarter valued at about $231,000. 92.79% of the stock is currently owned by hedge funds and other institutional investors.
Ingevity Company Profile
Ingevity Corporation manufactures and sells specialty chemicals and carbon materials in the United States and internationally. The company operates through two segments, Performance Materials and Performance Chemicals. The Performance Materials segment engineers, manufactures, and sells wood-based chemically activated carbon products primarily for gasoline vapor emission control systems.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.